Ikaria plots $200M IPO

Undaunted by the lower-than-expected debuts of other biotech IPOs, Ikaria has filed for a $200 million IPO. The New Jersey-based company, which also has R&D operations in Seattle, plans to trade on NASDAQ under ticker symbol IKAR. Unlike most biotechs, Ikaria actually generates revenue through its INOtherapy program, which includes INOMAX, the only FDA-approved treatment for hypoxic respiratory failure associated with pulmonary hypertension in term and near-term...